Singapore AUM Biosciences sees opportunities in Asia and India

"AUM is set to leverage on software expertise in the technology hubs of India. We are working on a win-win situation, taking Indian expertise along with our journey through the Silicon Valley and American funding to be a global service provider in the bioscience industry," Vishal Doshi, CEO, Co-founder, told

PTI

November 18, 2021 / 09:32 IST

Singapore-based AUM Biosciences, having recently closed funding of USD27 million for global cancer drug development, sees a lot of untapped opportunities in Asia and India.

"AUM is set to leverage on software expertise in the technology hubs of India. We are working on a win-win situation, taking Indian expertise along with our journey through the Silicon Valley and American funding to be a global service provider in the bioscience industry," Vishal Doshi, CEO, Co-founder, told

PTI

first published: Nov 18, 2021 09:30 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347